AKAO Achaogen Inc.

-0.01  -2%
Previous Close 0.52
Open 0.52
Price To Book 1.31
Market Cap 32298382
Shares 63,206,227
Volume 837,558
Short Ratio
Av. Daily Volume 1,642,838

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial delayed due to decision to run a further Phase 1 trial first - noted May 4, 2018.
Complicated urinary tract infections (cUTI) due to multi-drug resistant (MDR) pathogens
FDA approval for cUTI but CRL received for the treatment of bloodstream infection (BSI).
Complicated urinary tract infections (cUTI)
Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
Plazomicin - CARE
Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE)

Latest News

  1. Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2018 Financial Results on March 28, 2019
  2. Does Achaogen, Inc. (NASDAQ:AKAO) Have A High Beta?
  3. Achaogen Announces Publication of Plazomicin Phase 3 CARE Study Results in the New England Journal of Medicine
  4. Achaogen Announces ZEMDRI® (plazomicin) Pivotal Phase 3 Study Results Published in the New England Journal of Medicine
  5. Achaogen Announces Closing of $15 Million Underwritten Public Offering
  6. Achaogen Announces Presentations at Two Upcoming Investor Healthcare Conferences
  7. Achaogen Announces Pricing of $15 Million Underwritten Public Offering
  8. Achaogen Announces Proposed Public Offering of Common Stock
  9. Achaogen Submits Response to ASPR/BARDA Request for Information (RFI) for Antimicrobial Resistance Project BioShield
  10. Achaogen Provides Update on Corporate Progress and Key Preliminary Fourth Quarter 2018 Results
  11. Why are deep-pocketed biotechs cutting hundreds of jobs?
  12. Could Achaogen, Inc.’s (NASDAQ:AKAO) Investor Composition Influence The Stock Price?
  13. Today's Research Reports on Trending Tickers: Achaogen and Arcadia Biosciences
  14. Achaogen Announces FDA Clearance and Launch of the Thermo Scientific QMS Plazomicin Immunoassay
  15. Recent Analysis Shows Best Buy Co., News Corporation, Semtech, Achaogen, Infosys, and Galapagos NV Market Influences — Renewed Outlook, Key Drivers of Growth
  16. Edited Transcript of AKAO earnings conference call or presentation 8-Nov-18 1:30pm GMT
  17. Health Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics
  18. Achaogen Announces Multiple Plazomicin Presentations at the American Society of Health Systems Pharmacists (ASHP) Midyear Clinical Meeting
  19. Achaogen Announces Presentations at Two Investor Healthcare Conferences in November
  20. Achaogen (AKAO) Reports Q3 Loss, Misses Revenue Estimates